Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1389 free, full-text research articles on human participants. First 3 results:

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
 

Author(s): William V Padula, Richard A Larson, Stacie B Dusetzina, Jane F Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C Müller, Dietger Niederwieser, Susanne Saussele, Charles A Schiffer, Richard T Silver, Bengt Simonsson, Rena M Conti

Journal:

 

We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib's price is expected to drop 70% to 90%. We hypothesized ...

Last Updated: 5 Mar 2016

Go To URL
Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
 

Author(s): Alessandra Chiarenza, Fabrizio Manetti, Elena Petricci, Martial Ruat, Antonella Naldini, Maurizio Taddei, Fabio Carraro

Journal:

 

The most relevant therapeutic approaches to treat CML rely on the administration of tyrosine kinase inhibitors (TKIs) like Imatinib, which are able to counteract the activity of Bcr-Abl protein increasing patient's life expectancy and survival. Unfortunately, there are some issues ...

Last Updated: 3 Mar 2016

Go To URL
Second primary malignancies in chronic myeloid leukemia patients.
 

Author(s): Tugce Caliskan, Ahmet Emre Eskazan

Journal: J Cancer Res Ther. ;11(4):1042.

 

Last Updated: 17 Feb 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 149 free, full-text review articles on human participants. First 3 results:

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
 

Author(s): Marialuisa Polillo, Sara Galimberti, Claudia Baratè, Mario Petrini, Romano Danesi, Antonello Di Paolo

Journal:

 

Chronic myeloid leukemia was the first haematological neoplasia that benefited from a targeted therapy with imatinib nearly 15 years ago. Since then, several studies have investigated the role of genes, their variants (i.e., polymorphisms) and their encoded proteins in the pharmacokinetics ...

Last Updated: 25 Sep 2015

Go To URL
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature.
 

Author(s): L Wang, F Du, H-M Zhang, H-X Wang

Journal: Braz. J. Med. Biol. Res.. 2015 Jul;48(7):583-7.

 

We report the case of a father and son diagnosed with atypical chronic myeloid leukemia (aCML). Both patients harbored SETBP1 mutations, which are present in 24.3% of aCML patients. Moreover, both shared the variant encoding p.Pro737His, but the aCML severity was greater in the son ...

Last Updated: 9 Jul 2015

Go To URL
Diagnosing and managing advanced chronic myeloid leukemia.
 

Author(s): Michael W Deininger

Journal: Am Soc Clin Oncol Educ Book. 2015 ;():e381-8.

 

Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural history in the absence of effective therapy. Morphologically, transformation from CP-CML to AP/BP-CML is ...

Last Updated: 21 May 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
 

Status: Not yet recruiting

Condition Summary: Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Leukemia

 

Last Updated: 15 Jun 2016

Go to URL
Regional Central Database Recording of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 16 Aug 2016

Go to URL
Bosutinib in Elderly Chronic Myeloid Leukemia
 

Status: Not yet recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 13 Jul 2016

Go to URL